HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Use of lisdexamfetamine dimesylate in treatment of executive functioning deficits and chronic fatigue syndrome: a double blind, placebo-controlled study.

Abstract
The purpose of this study was to assess the efficacy of lisdexamfetamine dimesylate (LDX) for the treatment of executive functioning deficits in adults (ages 18-60) with chronic fatigue syndrome (CFS). The study's primary outcome measure was the Behavior Rating Inventory of Executive Function-Adult (BRIEF-A). Secondary outcome measures were standardized assessments of fatigue, pain and global functioning. Twenty-six adults who met criteria for CFS and had clinically significant executive functioning deficits were randomly assigned to a flexible morning dose (30, 50, 70 mg/day) of either placebo or LDX for a 6-week trial. The data were analyzed with standard analysis of variance (ANOVA) procedures. Participants in the LDX group showed significantly more positive change in BRIEF-A scores (Mchange=21.38, SD=15.85) than those in the placebo group (Mchange=3.36, SD=7.26). Participants in the active group also reported significantly less fatigue and generalized pain relative to the placebo group. Although future studies with LDX should examine whether these benefits generalize to larger, more diverse samples of patients, these results suggest that LDX could be a safe and efficacious treatment for the executive functioning deficits often associated with CFS. The possibility that dopaminergic medications could play an important role addressing the symptoms of CFS is also discussed.
AuthorsJoel L Young
JournalPsychiatry research (Psychiatry Res) Vol. 207 Issue 1-2 Pg. 127-33 (May 15 2013) ISSN: 1872-7123 [Electronic] Ireland
PMID23062791 (Publication Type: Journal Article, Randomized Controlled Trial)
CopyrightCopyright © 2012 Elsevier Ireland Ltd. All rights reserved.
Chemical References
  • Antipsychotic Agents
  • Lisdexamfetamine Dimesylate
  • Dextroamphetamine
Topics
  • Adult
  • Analysis of Variance
  • Antipsychotic Agents (pharmacology, therapeutic use)
  • Cognition Disorders (drug therapy)
  • Dextroamphetamine (therapeutic use)
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Executive Function (drug effects)
  • Fatigue Syndrome, Chronic (drug therapy)
  • Female
  • Follow-Up Studies
  • Humans
  • Lisdexamfetamine Dimesylate
  • Male
  • Middle Aged
  • Neuropsychological Tests
  • Psychiatric Status Rating Scales
  • Time Factors
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: